1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

FDA: Ingredient Safety Decisions Under PCPSA Could Differ From CIR

 
• By Lauren Nardella

Compared with the Cosmetic Ingredient Review, FDA could consider a wider selection of data in its ingredient safety evaluations under the Personal Care Products Safety Act, an FDA official says. Further, industry would have the burden of demonstrating reasonable certainty of no harm, a high bar to clear.

FDAEntrance_1200x675

The Personal Care Products Safety Act would better enable FDA to evaluate cosmetic ingredients and restrict those deemed unsafe, and its assessments would in some cases be more rigorous than those undertaken by the Cosmetic Ingredient Review, according to an agency official.

In an Oct. 5 letter responding to questions from PCPSA sponsor Sen. Dianne Feinstein, D-Calif., FDA’s Acting Associate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation